Jörg Neermann

NextGen Sciences Ltd. provides technologies and reagents for molecular biology and protein research. Its advanced products automate and simplify complex research techniques, saving time and resources, improving results, and accelerating discovery. The company was founded on January 28, 2000 by Kevin Auton and David Wigley and is headquartered in Huntingdon, the United Kingdom.

Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts.

Vectura GmbH manufactures and develops pharmaceutical therapies for airways diseases. It offers dry powder formulation technology, device technology, and development capabilities. The company was founded by Gerhard Scheuch in 1997 and is headquartered in Gemünden, Germany.

TopoTarget UK Ltd. engages in the discovery and development of drugs and therapies to treat cancer. It develops anti-cancer drugs for molecular mechanisms associated with the cell cycle, chromatin control and DNA damage. The company was founded in 2002 and is headquartered in Oxford, the United Kingdom.

Topotarget A/S is a biotechnology company that is engaged in the development and commercialization of novel drugs for the treatment of cancer. Its product belinostat is a novel histone deacetylase inhibitor which is used for cancer patients. The company was founded by Peter Buhl Jensen and Maxwell Sehested in 2000 and is headquartered in Copenhagen, Denmark.

Affimed NV Niederlassung Deutschland discovers and develops antibody-based therapeutic drugs. The firm generates and develops a pipeline of antibody product candidates based on proprietary technology platform. It offer therapeutic drugs that target autoimmune diseases and tumor cells. The company was founded in 2000 and is headquartered in Heidelberg, Germany.

Efficas Medical Foods & Nutrition LLC develops science-based consumer products for the nutritional management of the immune system for both humans and pets. Its products are non-prescription medical food and helps to provide relief from asthma and associated allergies. The company was founded by Nancy Fogg-Johnson and Alex Merolli in 2003 and is headquartered in Fullerton, CA.

Curetis GmbH operates as a molecular diagnostics company which focuses on the development and commercialization of products for diagnosing severe infectious diseases. The firm offers diagnostic solutions for hospitals and large-scale laboratories. Its products include Unyvero L4 Lysator, Unyvero C8 Cockpit, Unyvero A50 Analyzer, and Unyvero Application Cartridges. The company was founded by Andreas Boos, Johannes Bacher, Gerd Lüdke, and Anne Thews in August 2007 and is headquartered in Holzgerlingen, Germany.

Vivendy Therapeutics Ltd. develops enzyme replacement therapy and biological products. It has developed a specific recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS) that is specifically modified to improve enzyme activity-enhancing the efficacy of the therapy in MPS IVA significantl. The company was founded in March 2006 and is headquartered in Basel, Switzerland.

Avontec is a Phase 2 biopharmaceutical company focused on the development and commercialization of novel therapeutic treatments for inflammatory disease. Its clinical development programs include product candidates for multiple potential inflammatory indications. The two most advanced, AVT-01 in asthma and AVT-02 in psoriasis, have successfully advanced into Phase 2a clinical trials that the firm expects to be completed until the first half of 2008. In addition, there are several candidates in the pipeline based on Avontec's core decoy technology. Avontec operates based on a lean business model with a seasoned management team experienced in clinical development.

Vital Therapies, Inc. operates as a biotherapeutic company, which develops a cell-based therapy targeting the treatment of acute forms of liver failure. Its product candidate, ELAD System, is a human cell-based bio-artificial liver support system that operates outside the body or extracorporeal. The company was founded in May 2003 and is headquartered in San Diego, CA.

Ventaleon GmbH is a biotechnology company, which engages in the development of inhaled treatments against viral infections. Its products include LASAG (D,L-lysine acetylsalicylate • glycine), a lysin-salt formulation of well known acetyl salicylic acid. The company was founded by Gerhard Scheuch in 2012 and is headquartered in Gauting, Germany.

Kuros Biosurgery Holding AG operated as a medical technology company. It engaged in the development of biologic and biomaterial-based product candidates for localized therapy in trauma, spine and wound care. The company was founded by Marion Bavand, Didier Cowling, Dominik Ellenrieder, and Jeffrey Hubbel on April 3, 2008 and was headquartered in Zurich, Switzerland.

ViCentra BV engages in the development of medical devices. It focuses in creating devices for diabetes patients. The company was founded by Tim Oakes and Joseph John Cefai in 2013 and is headquartered in Utrecht, the Netherlands.

Immunic AG develops pharmaceuticals in the immunology space. The firm offers immune modulators to block TH17-and TH1-mediated immune and autoimmune responses. The company was founded by Andreas Muhler and Manfred Groppel in April 2016 and is headquartered in Martinsried, Germany.

EyeSense AG develops novel continuous blood glucose monitoring systems for diabetes patients. The firm's continuous glucose monitoring (CGM) gives a sense of security to diabetic patients. The company was founded by Achim Müller in 2006 and is headquartered in Basel, Switzerland.

ImCyse SA engages in the development of curative therapies in the field of immune and allergic pathologies. It offers a technological platform that helps develop medicinal products with potential benefits in all clinical circumstances where HLA class II restricted specific immunity can be causative of or contribute to damages to humans or animals. The firm's products are used in organ-specific autoimmunity, allergy, alloimmunity, cancer and infectious diseases. The company was founded in August 2010 by Jean-Marie R. Saint-Remy and is headquartered in Liege, Belgium.

Curexsys GmbH is a German company founded by molecular biologist Jens Gruber and biochemist Dr. Herbert Stadler. The company is based in Goettingen, Germany. The company aims to become a leading supplier for clinical grade exosomes in regenerative medicine and anti-aging therapies. Exosomes are extracellular, nanoscale vesicles that transfer information to neighboring cells and distant tissues. Curexsys is currently pursuing the development of several programs in three indications, focusing on the generation of clearly defined, characterized, and purified extracellular vesicles/exosomes from their proprietary iMSC lines derived from Evotec's iPSC platform.

IDEA AG develops pain therapeutics and biopharmaceutical drugs. The firm develops and commercializes non-invasive therapeutic drugs and the targeted pain therapeutics for arthritic and osteoporosis-related inflammation, chronic pain and diseases. Its technology platform is based on proprietary carriers applied on skin and engineered to diminish side effects and increase drug potency. The company founded by Gregor Cevc in 1993 and is headquartered in Munich, Germany.

LSP Management Group BV (LSP) is an independent European venture capital firm which was founded by Martijn Kleijwegt, Frits van der Have and Tom Schwarz in 1998. Headquartered in Amsterdam, the firm provides financing to early- to mid-stage life science companies.